Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

This editorial originally ran in fellow CNHI paper The (Sunbury). Individuals have long valued privacy for themselves and their families, while often — knowingly or unknowingly — giving it away. It is ...

Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

A bankruptcy court approved the $305M sale of 23andMe to a nonprofit led by Anne Wojcicki, raising questions about data ...

TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million bid for the 23andMe assets, which will not come with any company liabilities ...

The consumer privacy ombudsman in 23andMe’s sale of customers’ genetic data is defending his choice of counsel against ...

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge greenlighted the sale of the remnants of the firm, including its wealth of ...

Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had previously agreed to buy most of 23andMe’s assets for $256 million in ...

A federal judge on Thursday declined to block the bankruptcy sale of genetic testing company 23andMe to its co-founder Anne ...